Background: Reported human papillomavirus (HPV) vaccination coverage in England is high, particularly in girls offered routine immunisation at age 12 years. Serological surveillance can be used to validate reported coverage and explore variations within it and changes in serological markers over time.
Methods: Residual serum specimens collected from females aged 15-19 years in 2010-2011 were tested for anti-HPV16 and HPV18 IgG by ELISA. Based on these results, females were classified as follows: seronegative, probable natural infection, probable vaccine-induced seropositivity, or possible natural infection/possible vaccine-induced seropositivity. The proportion of females with vaccine-induced seropositivity was compared to the reported vaccination coverage.
Results: Of 2146 specimens tested, 1380 (64%) were seropositive for both types HPV16 and HPV18 and 159 (7.4%) positive for only one HPV type. The IgG concentrations were far higher for those positive for both HPV types than those positive for only one HPV type. 1320 (62%) females were considered to have probable vaccine-induced seropositivity. Among vaccine-induced seropositives, antibody concentrations declined with increasing age at vaccination and increasing time since vaccination.
Conclusions: The proportion of females with vaccine-induced seropositivity was closest to the reported 3-dose coverage in those offered the vaccination at younger ages, with a greater discrepancy in the older females. This suggests either some under-reporting of immunisations of older females and/or that partial vaccination (i.e. one- or two-doses) has provided high antibody responses in 13-17 year olds.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784902 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150107 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Assessment of Antibody Levels and Vaccine-induced Serologic Responses After Completion of Cancer Treatment in Pediatric Patients: A 6-Year Experience in Turkey on HAV, HBV, VZV, and MMR Vaccinations.
J Pediatr Hematol Oncol
January 2025
Department of Pediatric Oncology, Faculty of Medicine and Cancer Institute, Hacettepe University, Ankara, Turkey.
Objective: Childhood cancer treatment disrupts vaccination schedules and weakens or eliminates vaccine-induced immunity. In addition, post-treatment vaccine responses vary. This study aimed to assess post-treatment serum antibody levels and vaccine responses in children.
View Article and Find Full Text PDFPersistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus.
NPJ Vaccines
December 2024
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, China.
Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durability of the anti-HEV IgG response elicited by one or two doses in the participants with different baseline serostatus.
View Article and Find Full Text PDFQuantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
Vaccine
January 2025
Center of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Article Synopsis
- Epidemiological studies show that factors like pre-vaccination immune status, age, gender, and vaccination history affect how people respond to influenza vaccines, but results vary across different studies.* -
- A new Bayesian model was created to analyze the relationships between these host factors and antibody responses after vaccination, revealing that pre-vaccination antibody levels and vaccination history significantly affect post-vaccine antibody dynamics.* -
- The findings suggest that individuals who have been vaccinated less frequently and have lower pre-vaccination antibody levels experience longer durations of effective protection (seroprotection) from the vaccine, with notable differences observed in antibody response to different influenza subtypes.*
Inactivated nanovaccine boosts T-cell memory response in a seropositive yellow-footed rock wallaby () - A case report from Copenhagen Zoo.
Int J Parasitol Parasites Wildl
December 2024
Vaxinano SAS, 84 Rue Du Dr Yersin, 59120, Loos, France.
is a ubiquitous parasite causing significant mortality in captive wildlife, especially marsupials. Historically, treatment has been unrewarding and no vaccine was available. An intranasal vaccine based on purified inactivated was developed for toxoplasmosis prevention.
View Article and Find Full Text PDFGenome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank.
Nat Commun
October 2024
Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.
Article Synopsis
- - The study investigated how genetics affects COVID-19 vaccine effectiveness by analyzing UK Biobank data, focusing on vaccine-induced seropositivity and breakthrough infections.
- - Researchers conducted four genome-wide association studies, finding connections between the HLA region and antibody response after vaccination, as well as identifying specific genomic regions linked to breakthrough infections and severity.
- - The results emphasize the importance of individual genetic differences in vaccine responses and help explain reasons for breakthrough infections despite vaccination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!